Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging placebo-controlled double-blind study of GV101 for weight loss in otherwise healthy adults with obesity
MOH_2025-05-26_014019Phase 2Not yet recruiting
- Sponsor
- Graviton Biosciences
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TDI01 in obesity (3 arms), sponsored by Graviton Biosciences. Primary endpoints: Safety, Pharmacokinetics and 1 more. Planned start May 2025; status: not yet recruiting.
02
Drugs
TDI01
03
Conditions
obesity
Beyond the preview
Go deeper on MOH_2025-05-26_014019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-05-26_014019.